ACADIA Pharmaceuticals
Price & Volume
Stats
See moreOpen | $26.31 |
Previous Close | $26.41 |
Day Range | $24.95-$26.51 |
52W Range | $19.69-$30.96 |
Market Cap | $4.5B |
Shares Short | 9M |
Financials
See moreRevenue (12 Mos) | $1.1B |
Revenue Growth (YoY) | 16.4% |
Gross Profit (12 Mos) | $706.6M |
Diluted EPS | $2.23 |
News
See moreYahoo Finance • 13 hours ago
Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue
Yahoo Finance • 23 days ago
AcadeMedia (OM:ACAD) Reports Stronger Results, Is The 19% Upside Still There?
Yahoo Finance • 30 days ago
Acadia Gets European Commission Nod for Daybu in Rett Syndrome
Yahoo Finance • 2 months ago
Acadia outlines $480M-$510M 2026 DAYBUE sales outlook as remlifanserin Phase II data nears Sep-Oct
About
CEO | Ms. Catherine E. Owen Adams |
CFO | Mr. Mark C. Schneyer |
Address | 12830 El Camino Real, San Diego, CA, United States, 92130 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 796 |